Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

SABCS 2012

2 Dec 2011
The Westin Prince, Toronto, Toronto, Canada
Neurocognitive impact in adjuvant chemotherapy for breast cancer
Prof Bernadine Cimprich - University of Michigan School of Nursing, Ann Arbor, U...
Neurocognitive impact in adjuvant chemotherapy for breast cancer  ( Prof	Bernadine	Cimprich - University of Michigan School of Nursing, Ann Arbor, USA )
17 Dec 2012
Predicting late distant metastases in ER / HER2- breast cancer patients
Dr Peter Dubsky - Medical University of Vienna, Austria
Predicting late distant metastases in ER / HER2- breast cancer patients ( Dr Peter Dubsky - Medical University of Vienna, Austria )
17 Dec 2012
Investigation of Ki67 biomarker
Dr Torsten Nielsen - University of British Columbia, Vancouver, Canada
Investigation of Ki67 biomarker ( Dr Torsten Nielsen - University of British Columbia, Vancouver, Canada )
17 Dec 2012
Results of a randomised phase 2 study of PD 0332991
Dr Richard Finn - Universtity of California, Los Angeles, USA
Results of a randomised phase 2 study of PD 0332991 ( Dr Richard Finn - Universtity of California, Los Angeles, USA )
17 Dec 2012
Eribulin fails to demonstrate superiority over capecitabine in advanced breast c...
Dr Peter Kaufman – Norris-Cotton Cancer Center, Lebanon, USA
Eribulin fails to demonstrate superiority over capecitabine in advanced breast cancer ( Dr Peter Kaufman – Norris-Cotton Cancer Center, Lebanon, USA )
16 Dec 2012
Mammographic density and the risk and detection of breast cancer
Dr Norman Boyd – University of Toronto, Canada
Mammographic density and the risk and detection of breast cancer ( Dr Norman Boyd – University of Toronto, Canada )
16 Dec 2012
Validation of genomic grade index histological grading in invasive breast cancer
Prof Christos Sotiriou – Jules Bordet Institute, Brussels, Belgium
Validation of genomic grade index histological grading in invasive breast cancer ( Prof Christos Sotiriou – Jules Bordet Institute, Brussels, Belgium )
16 Dec 2012
Results of the TACT2 and BEATRICE breast cancer trials
Prof David Cameron – Edinburgh University, UK
Results of the TACT2 and BEATRICE breast cancer trials ( Prof David Cameron – Edinburgh University, UK )
16 Dec 2012
Influence of low penetrant factors on overall cancer risk
Prof Douglas Easton – Cancer Research UK Genetic Epidemiology Unit, Cambridge Un...
Influence of low penetrant factors on overall cancer risk ( Prof Douglas Easton – Cancer Research UK Genetic Epidemiology Unit, Cambridge University, UK )
16 Dec 2012
Diverse genetic alterations found in triple-negative breast cancers after neoadj...
Dr Justin Balko – Vanderbilt-Ingram Cancer Center, Nashville, USA
Diverse genetic alterations found in triple-negative breast cancers after neoadjuvant chemo ( Dr Justin Balko – Vanderbilt-Ingram Cancer Center, Nashville, USA )
16 Dec 2012
A new oestrogen receptor protein target
Dr Jason Carroll – University of Cambridge, UK
A new oestrogen receptor protein target ( Dr Jason Carroll – University of Cambridge, UK )
16 Dec 2012
Ethical issues associated with genomic sequencing
Dr James Evans – University of North Carolina, Chapel Hill, USA
Ethical issues associated with genomic sequencing ( Dr James Evans – University of North Carolina, Chapel Hill, USA )
16 Dec 2012
Links between EGFR/HER1 signalling and trastuzumab efficacy
Dr David Rimm – Yale University, New Haven, USA
Links between EGFR/HER1 signalling and trastuzumab efficacy ( Dr David Rimm – Yale University, New Haven, USA )
16 Dec 2012
Use of FDG PET imaging
Dr David Mankoff - University of Pennsylvania, Philadelphia
Use of FDG PET imaging ( Dr David Mankoff - University of Pennsylvania, Philadelphia )
16 Dec 2012
Effects of obesity in breast cancer patients
Dr Clifford Hudis – Memorial Sloan Kettering Cancer Center, New York, USA
Effects of obesity in breast cancer patients ( Dr Clifford Hudis – Memorial Sloan Kettering Cancer Center, New York, USA )
14 Dec 2012
The AZURE translational study
Prof Robert Coleman - Weston Park Hospital, University of Sheffield, UK
The AZURE translational study ( Prof Robert Coleman	 - Weston Park Hospital, University of Sheffield, UK )
14 Dec 2012
Diagnosis of blood cancer after a breast cancer diagnosis
Prof Antonio Wolff - The Johns Hopkins Hospital, Baltimore, USA
Diagnosis of blood cancer after a breast cancer diagnosis ( Prof Antonio Wolff - The Johns Hopkins Hospital, Baltimore, USA )
14 Dec 2012
HDAC inhibition sensitises triple-negative breast cancer cells to PARP inhibitio...
Dr Kapil Bhalla - University of Kansas Cancer Center, Kansas City, USA
HDAC inhibition sensitises triple-negative breast cancer cells to PARP inhibition ( Dr Kapil Bhalla - University of Kansas Cancer Center, Kansas City, USA )
13 Dec 2012
A need for clarity in clinical trial end points
Dr Clifford Hudis – Memorial Sloan Kettering Cancer Center, New York, USA
A need for clarity in clinical trial end points ( Dr Clifford Hudis – Memorial Sloan Kettering Cancer Center, New York, USA )
13 Dec 2012
Neratinib shows beneficial effects in the treatment of HER2 mutated breast cance...
Prof Ron Bose – Washington University School of Medicine, St. Louis, USA
Neratinib shows beneficial effects in the treatment of HER2 mutated breast cancer ( Prof Ron Bose – Washington University School of Medicine, St. Louis, USA )
12 Dec 2012
Adjuvant chemotherapy for locally recurrent breast cancer
Dr Stefan Aebi – Luzerner Kantonsspital, Switzerland
Adjuvant chemotherapy for locally recurrent breast cancer ( Dr Stefan Aebi – Luzerner Kantonsspital, Switzerland )
12 Dec 2012
Breast cancer hypo-fractionated radiotherapy offers long-term tumour control
Prof John Yarnold – Institute of Cancer Research and Royal Marsden Hospital, UK
Breast cancer hypo-fractionated radiotherapy offers long-term tumour control ( Prof John Yarnold – Institute of Cancer Research and Royal Marsden Hospital, UK )
12 Dec 2012
Effectiveness of sentinel lymph node surgery after chemotherapy in node-positive...
Dr Judy Boughey – Mayo Clinic, Rochester USA
Effectiveness of sentinel lymph node surgery after chemotherapy in node-positive breast cancer ( Dr Judy Boughey – Mayo Clinic, Rochester USA )
12 Dec 2012
Extending adjuvant trastuzumab treatment time provided no additional benefit
Prof Martine Piccart - Jules Bordet Institute, Brussels, Belgium
Extending adjuvant trastuzumab treatment time provided no additional benefit ( Prof Martine Piccart - Jules Bordet Institute, Brussels, Belgium )
12 Dec 2012
Breast cancer genome sequencing identified HER2 mutations as targets for drug tr...
Prof Ron Bose - Washington University School of Medicine, St Louis, USA
Breast cancer genome sequencing identified HER2 mutations as targets for drug treatment ( Prof Ron Bose - Washington University School of Medicine, St Louis, USA )
12 Dec 2012
Cognitive problems may be present before chemotherapy in women with breast cance...
Prof Bernadine Cimprich - University of Michigan School of Nursing, Ann Arbor, U...
Cognitive problems may be present before chemotherapy in women with breast cancer ( Prof Bernadine Cimprich - University of Michigan School of Nursing, Ann Arbor, USA )
12 Dec 2012
BEATRICE study, adjuvant bevacizumab did not improve invasive disease-free survi...
Prof David Cameron - Edinburgh University, UK
BEATRICE study, adjuvant bevacizumab did not improve invasive disease-free survival in triple-negative breast cancer ( Prof David Cameron - Edinburgh University, UK )
12 Dec 2012
Phase III trial did not show superiority of eribulin compared with capecitabine ...
Dr Peter Kaufman - Norris Cotton Cancer Center, New Hampshire, USA
Phase III trial did not show superiority of eribulin compared with capecitabine in metastatic breast cancer ( Dr Peter Kaufman - Norris Cotton Cancer Center, New Hampshire, USA )
12 Dec 2012
HDAC inhibitors sensitise triple-negative breast cancer cells to PARP inhibition...
Dr Kapil Bhalla - University of Kansas Cancer Center, Kansas City, USA
HDAC inhibitors sensitise triple-negative breast cancer cells to PARP inhibition and cisplatin treatment ( Dr Kapil Bhalla - University of Kansas Cancer Center, Kansas City, USA )
6 Dec 2012
Diverse genetic alterations in triple-negative breast cancers after neoadjuvant ...
Dr Justin Balko - Vanderbilt-Ingram Cancer Center, Nashville, USA
Diverse genetic alterations in triple-negative breast cancers after neoadjuvant chemotherapy ( Dr Justin Balko - Vanderbilt-Ingram Cancer Center, Nashville, USA )
6 Dec 2012
Young women with breast cancer more likely to respond to neoadjuvant chemotherap...
Prof Sibylle Loibl - University of Frankfurt, Frankfurt, Germany
Young women with breast cancer more likely to respond to neoadjuvant chemotherapy ( Prof Sibylle Loibl - University of Frankfurt, Frankfurt, Germany )
6 Dec 2012
Chemo after complete surgical removal of local or regional breast cancer recurre...
Dr Stefan Aebi - Luzerner Kantonsspital, Luzern, Switzerland
Chemo after complete surgical removal of local or regional breast cancer recurrence increases survival rates ( Dr Stefan Aebi - Luzerner Kantonsspital, Luzern, Switzerland )
6 Dec 2012
Fewer, bigger doses of radiotherapy benefit cancer patients
Prof John Yarnold - Institute of Cancer Research and Royal Marsden Hospital, UK
Fewer, bigger doses of radiotherapy benefit cancer patients ( Prof John Yarnold - Institute of Cancer Research and Royal Marsden Hospital, UK )
6 Dec 2012